Michel Vounatsos

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates. Biogen reported quarterly revenue of $2.73 billion, which beat the estimate of $2.62 billion. The company...

Biogen Inc (NASDAQ: BIIB) CEO Michel Vounatsos appeared Monday on CNBC's "Power Lunch" to discuss the company's FDA approval announcement.  What Happened: Biogen announced the FDA granted accelerated approval for the company's Aduhelm treatment as the...

Insider buying can be an encouraging signal for potential investors. Some health care related companies saw notable insider buys last week Some chief executive officers were stepping up to the buy window as well. Conventional wisdom says that insiders and 10 percent owners really only buy shares...

Biogen Inc (NASDAQ: BIIB) is the latest biotech company to jump onto the gene therapy bandwagon. What To Know Biogen, which focuses on developing therapies for neurological and neurodegenerative diseases, has agreed to acquire U.K.-based gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE...

Following an announcement by Biogen Inc (NASDAQ: BIIB) elevating Michel Vounatsos, the company's chief commercial officer and a recent hire from Merck & Co., Inc. (NYSE: MRK), as CEO, Jefferies said the near-term potential for a takeout is reduced. The firm continues to see the reward/...